Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 125 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurotoxicity Clear all
Completed Phase 3 Interventional

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

NCT00305188
View directory record Official record
Conditions
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
Interventions
Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Jul 22, 2026, 2:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT05237986
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 2:22 PM EDT
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 2:22 PM EDT
Completed No phase listed Observational

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

NCT01982591
View directory record Official record
Conditions
Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Paoli, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

NCT00365768
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
Glutamine, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jul 22, 2026, 2:22 PM EDT
Withdrawn Not applicable Interventional

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

NCT01923376
View directory record Official record
Conditions
Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status, AMS
Interventions
Lactulose, Polyethylene Glycol 3350
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

NCT00255879
View directory record Official record
Conditions
Dyskinesia, Drug-Induced
Interventions
Quetiapine, Risperidone, Olanzapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Jul 22, 2026, 2:22 PM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00516503
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
baclofen/amitriptyline/ketamine gel, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
165
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Jul 22, 2026, 2:22 PM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 22, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway

NCT01499940
View directory record Official record
Conditions
Neurotoxicity
Interventions
Vitamin D3
Drug
Lead sponsor
Gerald Higa, PharmD.
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jul 22, 2026, 2:22 PM EDT
Withdrawn Phase 2 Interventional

Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study

NCT00627133
View directory record Official record
Conditions
Seizure, Alcohol Related
Interventions
levetiracetam
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
390
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Study of Human Botulism Immunoglobulin in Infants With Botulism

NCT00004401
View directory record Official record
Conditions
Infant Botulism, Botulism
Interventions
botulism immune globulin
Drug
Lead sponsor
California Department of Health Services
Other
Eligibility
Up to 1 Year
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00489411
View directory record Official record
Conditions
Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
475
States / cities
Antioch, California • Berkeley, California • Burlingame, California + 328 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

NCT01701999
View directory record Official record
Conditions
Botulism
Interventions
rBV A/B
Biological
Lead sponsor
California Department of Public Health
Other
Eligibility
18 Years to 69 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Richmond, California • West Jefferson, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

NCT00058071
View directory record Official record
Conditions
Gestational Trophoblastic Tumor, Neurotoxicity, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
57
States / cities
Burbank, California • La Jolla, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Jul 22, 2026, 2:22 PM EDT
Terminated Phase 1 Interventional

Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases

NCT00469937
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Neurotoxicity, Solid Tumor
Interventions
lithium carbonate, cognitive assessment, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 22, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

NCT07390071
View directory record Official record
Conditions
Lymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Home Automated Telemanagement (HAT) Patient Unit
Device
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Multiple Myeloma
Interventions
Audio Tasks
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 2:22 PM EDT
Not yet recruiting Not applicable Interventional

Assessing DCog Short for Neurotoxicity in CAR-T

NCT07403812
View directory record Official record
Conditions
Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
DCog Short
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 22, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Results available

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

NCT03461445
View directory record Official record
Conditions
Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
Interventions
Envarsus, IR Tacrolimus
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
60 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 22, 2026, 2:22 PM EDT
Active, not recruiting Early Phase 1 Interventional

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

NCT04514029
View directory record Official record
Conditions
Lymphoma
Interventions
Simvastatin, Dexamethasone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 2:22 PM EDT
Completed No phase listed Observational

Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery

NCT01417507
View directory record Official record
Conditions
Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Cognitive/Functional Effects, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Seizure
Interventions
cognitive assessment, magnetic resonance imaging, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Procedure · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 22, 2026, 2:22 PM EDT